Reporting of Harm in Randomized Controlled Trials Published in the Urological Literature
Authors:
- 1 May 2010
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 183 (5) , 1693-1697
Abstract
Evidence-based decision making seeks to balance potential benefits and harms (adverse effects) of health care interventions for an individual patient. We determined the prevalence and completeness of harm reporting in randomized controlled trials in the urological literature. We performed a systematic literature search of all randomized controlled trials of therapeutic interventions published in The Journal of Urology, Urology, European Urology and BJU International in 1996 and 2004. Each article was reviewed by 2 independent investigators for 10 harm reporting criteria recommended by the CONSORT group. Discrepancies were settled by discussion and consensus. A total of 152 randomized controlled trials met the inclusion criteria, of which 109 (72%) reported adverse event outcomes. The median number of harm reporting criteria satisfied improved marginally from 1996 to 2004 (2.8 to 3.3, p = 0.36). A large proportion of studies failed to address harm in the abstract (55, 36%), introduction (71, 47%) and discussion (52, 34%). Few studies specified which adverse events were evaluated (21, 14%), when harm information was collected (32, 21%) or how the harm was attributed to the intervention (5, 3%). Only 48 (32%) articles provided reasons for patient withdrawal and 1 in 5 (33, 22%) reported the severity of adverse events. Randomized controlled trials published in the urological literature contain significant deficiencies in adverse event reporting. These findings suggest the need for reporting standards for harm in urological journals. Improvements in adverse event reporting would permit a more balanced assessment of interventions and would enhance evidence-based urological practice.Keywords
This publication has 16 references indexed in Scilit:
- Reporting of harm in randomized controlled trials evaluating stents for percutaneous coronary interventionTrials, 2009
- How to Use a Clinical Practice GuidelineJournal of Urology, 2009
- Reporting of harms and adverse events in otolaryngology journalsOtolaryngology–Head and Neck Surgery, 2009
- Published randomized controlled trials of drug therapy for dementia often lack complete data on harmJournal of Clinical Epidemiology, 2008
- Going from evidence to recommendationsBMJ, 2008
- Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT StatementAnnals of Internal Medicine, 2004
- Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health ResearchCanadian Medical Association Journal, 2004
- Grading quality of evidence and strength of recommendationsBMJ, 2004
- Empirical Evidence for Selective Reporting of Outcomes in Randomized TrialsJAMA, 2004
- The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and ElaborationAnnals of Internal Medicine, 2001